Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6152W HIGH $1.65
Volume
19.75 M
Value Traded
57.66 K
Short % Float
1.48%
+39.41%Week
+28.71%1 Month
-21.58%3 Month
-14.73%6 Month
-86.88%5 Year
-90.15%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.43 M
EPS (TTM)
-0.20
P/E Ratio
-
Ent. Value
14.54 M
Total Shares
17.56 M
Float Shares
10.86 M
Insiders
38.15%
Institutions
17.86%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IRIX Catalyst Timeline
Dated clinical, regulatory and corporate events for IRIDEX Corporation
Past FDA Catalysts and PDUFA Decisions
How IRIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
IRIDEX Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IRIX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dizon Romeo ROfficer (Chief Financial Officer) | Buy | 7,900 185,306 held | $0.63 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IRIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IRIX for Q2 2026. | ||||
IRIX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IRIX ranks across every disease it competes in
Competitive Position is a premium feature
See how IRIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIRIX News
IRIX▲ +7.3%on this news
Iridex Completes Relocation of Manufacturing Facility to San Jose, California
Iridex Corporation has successfully relocated its manufacturing facility from Mountain View to San Jose, California. This move is part of a strategy to reduce expenses and enhance profitability. The company expects to achieve around $0.6 million in annual cost savings and aims for improved operational efficiency with the new infrastructure. The transition is anticipated to yield further savings as operations are fully integrated.
Read more →IRIX▼ -15.8%on this news
Iridex Reports Second Quarter 2026 Financial Results
Iridex Corporation reported its financial results for Q2 2026, showing total revenue of $12.6 million, a 7% decline from the previous year. The Cyclo G6 product family saw a 19% revenue increase, but overall performance was affected by weaker retina product sales. The company remains optimistic about future growth, particularly in glaucoma treatments, despite current challenges.
Read more →IRIXIridex to Report Second Quarter 2026 Financial Results on August 18, 2026
Iridex Corporation will release its financial results for Q2 2026 on August 18, 2026. A conference call will follow at 2:00 p.m. PT to discuss the results and provide a business update. The company specializes in laser-based medical systems for treating eye conditions.
Read more →IRIXIridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
Iridex Corporation has expanded its EyeProGPO product offering to include EndoProbe Handpieces, providing over 4,300 members with preferred pricing. These single-use devices are designed for use with Iridex laser consoles in treating retinal disorders. The addition reflects a commitment to enhancing access to innovative technologies in ophthalmology.
Read more →IRIXIridex to Present at the Planet MicroCap Las Vegas 2026 Conference
Iridex Corporation will present at the Planet MicroCap Las Vegas 2026 Conference on June 17. The presentation will be accessible via a live and archived webcast. Iridex specializes in laser-based medical systems for treating glaucoma and retinal diseases, showcasing their innovative MicroPulse technology.
Read more →IRIXIridex Reports First Quarter 2026 Financial Results 2026 Guidance Affirmed
Iridex Corporation reported its financial results for the first quarter ending April 4, 2026, revealing a slight revenue decline to $11.8 million compared to the previous year. Key growth was noted in the Cyclo G6 product family, but the total revenue was impacted by decreased retina system sales due to supply chain and regulatory delays. Operating expenses were reduced by 4%, contributing to a positive outlook for cash flow in the fiscal year. The company has reaffirmed its annual revenue guidance of $51 million to $53 million, factoring in market disruptions in the Middle East that affect product delivery timelines.
Read more →IRIXIridex to Report First Quarter 2026 Financial Results on May 19, 2026
Iridex Corporation has announced its plans to release financial results for the first quarter of 2026 on May 19, 2026. Following the announcement, the management team will host a conference call to discuss the results and provide a business update. Investors can participate via phone or through a live webcast on the company's website.
Read more →IRIXIridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology
Iridex Corporation has partnered with EyeProGPO to provide its members with preferred pricing on advanced retina laser technologies. This collaboration aims to enhance access to Iridex's laser products, including the PASCAL® and IQ laser platforms, thereby improving operational efficiency for ophthalmology practices. The partnership underscores Iridex's commitment to supporting healthcare providers with innovative solutions.
Read more →IRIX▼ -26.7%on this news
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
Iridex Corporation reported strong financial results for Q4 and full year 2025, with a 16% increase in revenue driven by higher sales in its retina and glaucoma product lines. The company achieved positive adjusted EBITDA for the first time, while also reducing operating expenses. However, gross margins declined due to rising manufacturing costs and the company anticipates challenges in 2026 due to market disruptions in the Middle East.
Read more →IRIXIridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026
Iridex Corporation has announced it will release its financial results for Q4 and the full year of 2025 on March 26, 2026. The company will also provide a business update during a conference call scheduled for the same day. Investors can participate in the call or access a webcast through the company's website.
Read more →IRIXIridex Announces Plans to Relocate Headquarters
Iridex Corporation has announced plans to relocate its headquarters from Mountain View to San Jose, California. The move is expected to save approximately $0.4 million in fiscal year 2026 and $0.6 million annually thereafter. CEO Patrick Mercer emphasized the importance of reducing operating expenses and maintaining talent acquisition in the Bay Area. However, the lease terms remain non-binding and subject to change.
Read more →IRIX▲ +28.7%on this news
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 Demonstrating continued revenue growth, operational efficiencies and positive cash flow
Iridex Corporation announced preliminary unaudited operational and financial results for Q4 and full year 2025. The company expects total revenue between $52.5 million and $52.7 million, representing an increase of up to 8% compared to 2024. In Q4 alone, revenue is projected to rise by 15% to 17%, with positive cash flow reported. Additionally, Iridex highlighted successful sales of its Cyclo G6 products, indicating a strong market demand and operational efficiency. These results remain subject to final auditing and adjustments.
Read more →IRIXIridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
Iridex Corporation announced the publication of a study demonstrating the safety and effectiveness of retreatment using MicroPulse technology in glaucoma management. Conducted at the University Eye Clinic Maastricht, the study showed significant intraocular pressure reductions in patients after retreatment. The findings support MicroPulse TLT as a valuable option for patients experiencing diminished IOP-lowering benefits over time.
Read more →IRIXIridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse Technology and Continuous-Wave Laser for Glaucoma Treatment
Iridex Corporation announced a new study published in Translational Vision Science & Technology that examines the thermal dynamics of transscleral laser treatments for glaucoma. The study, led by Dr. Tomas M. Grippo, compares continuous wave transscleral cyclophotocoagulation and MicroPulse technology. Findings indicate that MicroPulse TLT offers a smaller thermal zone and lower peak temperatures, suggesting a potential for safer treatment. The research aims to enhance clinical practices for both laser techniques in glaucoma management.
Read more →IRIXIridex to Present at the Sidoti Year-End Virtual Investor Conference
Iridex Corporation has announced its participation in the Sidoti Year-End Virtual Investor Conference scheduled for December 11, 2025. During this event, management will present at 10:45 am ET, and interested parties will be able to access both live and archived webcasts via the company’s website. Iridex is noted for its advanced laser-based medical systems, particularly for treating glaucoma and retinal diseases, showcasing its position in the ophthalmology market.
Read more →IRIX▼ -19.8%on this news
Iridex Reports Third Quarter 2025 Financial Results
Iridex Corporation reported its third quarter 2025 financial results, showcasing an 8% year-over-year revenue increase driven by strong sales of glaucoma probes and the Pascal laser system. The company reduced operating expenses and anticipates a positive adjusted EBITDA for the full year. Despite a net loss, the outlook remains optimistic for cash flow and financial performance improvements.
Read more →IRIXIridex to Report Third Quarter 2025 Financial Results on November 11, 2025
Iridex Corporation, a leader in laser-based medical systems, is set to release its financial results for the third quarter of 2025 on November 11, 2025. Following the announcement, a conference call will be hosted by the management team for investors. This event is viewed as an opportunity for the company to provide insights into its business performance and operations in the ophthalmology market, particularly in treatments for glaucoma and retinal diseases.
Read more →IRIXIridex Corporation Receives Formal Notification of Nasdaq Listing Compliance
Iridex Corporation has received formal notification from Nasdaq confirming its compliance with continued listing requirements. This follows a previous notification of non-compliance due to insufficient stockholders' equity. The company has now met the minimum requirement of $2.5 million, closing the matter. Iridex specializes in laser-based medical systems for ophthalmology.
Read more →IRIXIridex Reports Second Quarter 2025 Financial Results
Iridex Corporation reported its financial results for the second quarter of 2025, showing a total revenue of $13.6 million, which is a 7% year-over-year increase. The company achieved a 14% sequential growth compared to the first quarter of 2025 and reported its third consecutive quarter of positive non-GAAP adjusted EBITDA. However, net loss improved slightly to $1.0 million, and the Cyclo G6 product family experienced flat revenue year-over-year. Looking ahead, Iridex aims to achieve cash flow breakeven and continue its focus on improving financial discipline and operational efficiency.
Read more →IRIXIridex to Report Second Quarter 2025 Financial Results on August 12, 2025
Iridex Corporation plans to announce its financial results for the second quarter of 2025 on August 12, 2025. The announcement will be followed by a conference call at 2:00 p.m. PT. The company specializes in laser-based medical systems for treating glaucoma and retinal diseases, with a strong international presence.
Read more →About IRIDEX Corporation
Headquarters1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA, 94043
BIOPHARMAWATCH ELITE PLUS
Trade the next IRIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime